Dry Eye Syndrome Market Projected to Reach CAGR of 7.30% Forecast by 2029

In this Global Dry Eye Syndrome market report, industry trends have been explained on the macro level which makes it possible to summarize the market landscape and probable future issues. The report analyses and estimates general market drivers in the form of consumer demand, government policy and demand which are related to consumer buying pattern and thereby market growth and development. This market research report contains thorough analysis of market and numerous related factors that range from market drivers, market restraints, market segmentation, opportunities, challenges, and market revenues to competitive analysis. Global Dry Eye Syndrome report is also useful when launching a new product or expanding the business regionally or globally.

Data Bridge Market Research analyses that the dry eye syndrome market was valued at USD 4.20 billion in 2021 and is expected to reach USD 7.38 billion by 2029, registering a CAGR of 7.30% during the forecast period of 2022 to 2029.

Dry eye syndrome, also known as keratoconjunctivitis sicca (KCS), is a condition in which the surface of the affected person's eyes lacks lubrication or moisture. It's a common ailment that can strike anyone at any time. Aching and burning sensations, sore eyes, red eyes, weary eyes, itchy eyes, photophobia, and other symptoms of dry eye can occur. Watery eyes can also be a symptom, as the dry surface of the eyes over-stimulates the production of the watery component of tears to compensate for the dryness.

Some of the major players operating in the dry eye syndrome market are:

Teva Pharmaceutical Industries Ltd ( Israel)

Sanofi (France)

Novartis AG (Switzerland)

Eli Lilly and Company (US)

Merck & Co., Inc. (US)

AstraZeneca (UK)

Johnson & Johnson Private Limited (US)

Abbott (US)

F. Hoffmann-La Roche Ltd. (Switzerland)

AbbVie Inc. (US)

Otsuka America Pharmaceutical, Inc. (US)

Pfizer Inc. (US)

GlaxoSmithKline plc (UK)

Merck KGaA (Germany)

Allergan (Ireland)

Akorn Operating Company LLC (US)

Allostera Pharma Inc. (Canada)

I-Med Pharma Inc. (Canada)

Santen Pharmaceuticals Co. Ltd., (Japan)

AFT Pharmaceuticals (New Zealand)

Novaliq GmbH (Germany)

Browse Full Report Along with Facts and Figures @ https://www.databridgemarketresearch.com/reports/global-dry-eye-syndrome-market

Global Dry Eye Syndrome Market Scope:

The dry eye syndrome market is segmented on the basis of product type, dosage type, drug class, dose, medication type, container type, packaging type, type, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

Tear stimulators

Artificial Tears

Secretagogue

Others

On the basis of product type, the market is segmented into tear stimulators, artificial tears, secretagogue and others.

Dosage Type

Liquid

Semi-solid

Others

On the basis of dosage type, the market is segmented into liquid, semi solid and others.

Drug Class

Lubricating Agent

Cholinergics

Anti-Inflammatory

Anti-Infectives

Anti-Allergics

Others

On the basis of drug class, the market is segmented into anti-inflammatory, lubricating agents, anti-infectives, anti-allergics, cholinergics and others.

Dose

Unit dose

Multi-dose

On the basis of dose, the market is segmented into multi dose and unit dose.

Medication Type

Prescription (Rx) Drugs

Over the Counter (OTC) Drugs

On the basis of medication type, the market is segmented into prescription (RX) drugs, and over the counter (OTC) drug.

Container Type

Unit-Dose Vials

Bottles

Tubes

On the basis of container type, the market is segmented into unit dose vials, bottles, and tubes.

Packaging Type

Plastic

Aluminium

Glass

On the basis of packaging type, the market is segmented into plastic, glass, and aluminium.

Type

Brands

Generics

On the basis of type, the market is segmented into generics and brands.

End-Users

Hospitals

Specialty Clinics

Homecare

Others

On the basis of end-users, the dry eye syndrome market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

On the basis of distribution channel, the dry eye syndrome market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Browse Trending Reports:

https://dbmr12232.blogspot.com/2023/05/obsessive-compulsive-disorder-ocd-drugs_31.html

https://dbmr12232.blogspot.com/2023/05/europe-obsessive-compulsive-disorder_31.html

https://dbmr12232.blogspot.com/2023/05/middle-east-and-africa-elderly-care_30.html

https://dbmr12232.blogspot.com/2023/05/europe-elderly-care-market-industry_30.html

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

United Kingdom: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

About Data Bridge Market Research:

An absolute way to predict what the future holds is to understand the current trend! Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are committed to uncovering the best market opportunities and nurturing effective information for your business to thrive in the marketplace. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is a set of pure wisdom and experience that was formulated and framed in 2015 in Pune.

Data Bridge Market Research has more than 500 analysts working in different industries. We have served more than 40% of the Fortune 500 companies globally and have a network of more than 5,000 clients worldwide. Data Bridge is an expert in creating satisfied customers who trust our services and trust our hard work with certainty. We are pleased with our glorious 99.9% customer satisfaction rating.

This release was published on openPR.